These results establish the validity of targeting nuclear transport to reduce hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and fatty liver in a murine model of LDL receptor deficiency. This evidence concerns the gene LDLR and familial hypercholesterolemia.